BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» Nimbus Therapeutics details discovery, discloses structure of selective TYK2 inhibitor NDI-034858
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
ACS Fall 2022
Nimbus Therapeutics details discovery, discloses structure of selective TYK2 inhibitor NDI-034858
Aug. 30, 2022
No Comments
The structure of a potent and selective TYK2 inhibitor, NDI-034858 (NTX-973), which was found clinically effective in autoimmune and inflammatory diseases, was disclosed for the first time by researchers from Nimbus Therapeutics LLC.
BioWorld Science
Conferences
Immune
Inflammatory